GRI Bio, Inc.GRIEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
GRI Bio, Inc. is a clinical-stage biopharmaceutical firm developing innovative targeted therapies for autoimmune, inflammatory, and fibrotic diseases. Its product candidates address unmet medical needs, serving global healthcare markets to deliver improved outcomes for patients with underserved disease indications.
GRI Q1 FY2023 Key Financial Metrics
Revenue
$16.0K
Gross Profit
N/A
Operating Profit
$-988.0K
Net Profit
$-2.1M
Gross Margin
N/A
Operating Margin
-6175.0%
Net Margin
-13437.5%
YoY Growth
N/A
EPS
$-15.04
GRI Bio, Inc. Q1 FY2023 Financial Summary
GRI Bio, Inc. reported revenue of $16.0K for Q1 FY2023, with a net profit of $-2.1M (down 611.9% YoY) (-13437.5% margin).
Key Financial Metrics
| Total Revenue | $16.0K |
|---|---|
| Net Profit | $-2.1M |
| Gross Margin | N/A |
| Operating Margin | -6175.0% |
| Report Period | Q1 FY2023 |
GRI Bio, Inc. Quarterly Revenue & Net Profit History
GRI Bio, Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2023 | $16.0K | — | $-2.1M | -13437.5% |
| Q3 FY2022 | $2.0K | — | $-351.0K | -17550.0% |
| Q2 FY2022 | $-1.0K | — | $-295.0K | 29500.0% |
| Q1 FY2022 | $0 | — | $-302.0K | N/A |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q1 2023 | |
|---|---|---|---|---|
| Revenue | $0 | $-1000 | $2000 | $16000 |
| YoY Growth | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q1 2023 | |
|---|---|---|---|---|
| Assets | $5.9M | $8.0M | $5.6M | $2.1M |
| Liabilities | $2.6M | $4.3M | $2.1M | $2.1M |
| Equity | $-5.2M | $-5.4M | $-5.7M | $-3.2M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q1 2023 | |
|---|---|---|---|---|
| Operating CF | $-2.3M | $2.2M | $-125000 | $-579000 |